tbuckley/cabot-search huggingface dataset:
Dendritic cell based vaccination in combination with IL-2 as a treatment for advanced renal cell carcinoma patients: Results from a phase I/II trial
Authors: A. Berntsen, P. Geertsen, R. Trepiakas, L. Wenandy, M. H. Andersen, P. T. Straten, T. Lorentzen, J. S. Johansen, H. E. Johnsen, I. M. Svane
Journal: Journal of Clinical Oncology (2006)

2575 Background: Autologous dendritic cells (DC) pulsed with tumor-associated antigens as peptides or tumor lysate derived proteins can induce generation of cytotoxic T-cells in cancer patients. Survivin and telomerase are tumor-associated antigens overexpressed in renal cell carcinoma, and telomerase and survivin derived HLA-A2 binding peptides are able to induce effector T-cells cytotoxic to tumor cells. Tumor lysate can be generated from allogeneic renal carcinoma cell lines and has a natural high amount of antigens potentially enabling the induction of a polyclonal immune response against multiple targets on tumor cells. Methods: Twenty-two patients with progressive metastatic renal cell carcinoma were included and toxicity and efficacy of DC-based immunotherapy were evaluated. HLA-A2 positive patients were treated with mature autologous DCs pulsed with a broad panel of HLA binding telomerase and survivin peptides and PADRE; HLA-A2 negative patients received DCs pulsed with allogeneic tumor lysate and KLH. The vaccines were administered intradermally or intranodally weekly/biweekly ten times and repeated monthly until tumor progression. Patients received low dose IL-2 as an adjuvant. Immune response was monitored using ELISPOT assay. IL-6 and the biomarker YKL-40 were measured in serum using ELISA assay. Results: Vaccinations were well tolerated. 17/22 patients were evaluable and 10 patients had stable disease (SD) for up to 11+ months (range 2–11+ months). Interestingly, serum IL-6 increased in patients with progressive disease compared with a decrease in patients with SD. After vaccination mean values of YKL-40 were 91ng/ml in patients with SD and 208ng/ml in patients with PD. Immune monitoring is ongoing and preliminary data demonstrate that peptide specific CTLs are induced by the treatment. Conclusions: This pilot study demonstrates, that vaccination with autologous DCs pulsed with tumour antigens is safe and without severe toxicity. Disease stabilization was observed in half of the treated patients. Serum IL-6 and YKL-40 values might be useful parameters to predict clinical response during vaccination therapy. No significant financial relationships to disclose.
Abstract 16787: Aneurysmal Dilatation of the Main Pulmonary Artery in Patients With Isolated Pulmonary Stenosis: An Intrinsic Arteriopathy or a Flow-Related Sequela?
Authors: Bram Ruijsink, Michela Miglianti, Phuoc Duong, Alessandra Frigiola
Journal: Circulation (2018)

Introduction: In patients with isolated pulmonary stenosis (iPS), dilatation of the MPA has been reported, sometimes developing into large aneurysms (giantPA). The incidence, aetiology, natural history, and its treatment. Methods: We identified all patients with iPS that attended our tertiary cardiac centre (one of the largest in the UK) between 2003 and 2018 and reviewed clinical notes, echocardiography and MRI data. We evaluated the incidence of MPA dilatation in patients with iPS and its relation to age and pulmonary valve (PV) function. Results: 197 patients (107 children, 90 adults) with iPS were identified. 122 (62%) underwent balloon dilatation of PV for severe stenosis (median age 0.65 IQR 0.08-5.18 years), 30 (15%) underwent PV repair or replacement (median age of 2.06 IQR 0.9-5.2 years) and 45 (22.8%) did not require any procedure. In patients that did not require a procedure, mean peak velocity on echocardiography was 2.55±0.65 m/sec. In patients that required an intervention, the MPA was normal to mildly dilated in most patients (mean z-score +1.2±2.6). In patients who did not undergo any procedure, the size of the MPA was only weakly correlated with age (R 2 .10 p &lt;.01) and severity of PV stenosis ( p &lt;.22). 12 patients (6% of total population) had giantPA (z-score &gt; 4 in children, diameter &gt; 50 mm in adults). Mean size of the largest diameter of the MPA was +5.8±1.9 z-score in children and 59±5 mm in adults. Of these patient 58% had undergone a procedure (mean age 11±14 yrs). Of note, while in the paediatric cohort the MPA size was easily obtained using echocardiography, in only 30% of adult patients the MPA was well visualized and there was a significant error (25±27%) in the provided measurements compared to 3D imaging obtained with MRI. In 7 of 8 adults with giantPA , diagnosis was made only with MRI. Conclusion: In patients with iPS, the incidence of giantPA is not negligible (at least 6%). MPA dilatation does not seem to correlate with PV function thus suggesting an underlying arteriopathy rather than a flow-related aetiology. In adults, MPA size is unreliably assessed using echocardiography. 3D imaging is therefore indicated in adults patients with iPS even in the presence of mild PV dysfunction. Total; word count : 1875 characters Figure 1: No impact of stenosis severity on MPA size in patient who did not undergo PV repair or replacement Figure 2: Aneurysmal dilatation of the MPA in a patient with isolated pulmonary stenosis (in this case mild stenosis).
Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
Authors: Ozan Yazici, Sercan Aksoy, Ozgul Ucar, Nuriye Özdemir, Mevlut Demir, Mehmet Ali Nahit Sendur, Zafer Arik, Sebnem Yaman, Tulay Eren, Dogan Uncu, Nurullah Zengin
Journal: Journal of Clinical Oncology (2013)

e20614 Background: Zoledronic acid (ZA) is one of the important biphosphanate which is widely used in bone metastatic cancer patients and osteoporotic patients. In a few studies it has been reported that treatment with biphosphonate was associated with an increased risk for atrial fibrillation. We aim to evaluate the arrhythmias that developed during infusion and immediately after infusion of the ZA. Methods: Bone metastatic 52 patients were included in study group. All of patients had totally 24 hour holter motorization during the first dose ZA infusion day. All of patients had 4 hours basal cardiac rhythm records before ZA infusion and about 19 hours after infusion. A short survey including demographic data and past medical history was completed. None of patients had clinically important arrhythmias before ZA infusion. We divided arrhythmias as supraventricular and ventricular. We evaluated arrhythmias pre, during and after ZA infusion. ZA were administered 4 mg IV in 15 minutes. Results: Thirty three of patients (63,5%) were male and 19 (36,5%) female. Median age of the patients was 52 (27-73). Most frequent cancers were breast (25%) and lung cancer (15,3%).Twelve (23%) patients had history of mediastinal radiotherapy. Three patients had history of myocardial infarction. In basal records we detected that twenty four of patients had supraventricular tachycardia (SVT) or ventricular premature systole (VPS). Fifteen of patients had SVT and fourteen had VPS during infusion period. After infusion period 48 of patients had SVT and 41 had VPS. Only 3 patients had none of arrhythmia after infusion. Three of the patients had sinusoidal arrhythmia and two had Mobitz type 2 bloc after infusion and also one of our patient who had no history of co morbidities and had SVT basal records, developed atrial fibrillation that refractory to medical cardioversion after 10 days of seventh dose ZA infusion. Conclusions: In this study we found that both SVT and VPS increased in cancer patients treated with ZA. Furthermore ZA may induce clinically important arrhythmias.
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
Authors: Cornelis J. M. Melief, Marij J. P. Welters, Ignace Vergote, Judith R. Kroep, Gemma G. Kenter, Petronella B. Ottevanger, Wiebren A. A. Tjalma, Hannelore Denys, Mariette I. E. van Poelgeest, Hans W. Nijman, Anna K. L. Reyners, Thierry Velu, Frederic Goffin, Roy I. Lalisang, Nikki M. Loof, Sanne Boekestijn, Willem Jan Krebber, Leon Hooftman, Sonja Visscher, Brent A. Blumenstein, Richard B. Stead, Winald Gerritsen, Sjoerd H. van der Burg
Journal: Science Translational Medicine (2020)

A strong vaccine-induced T cell response during standard-of-care chemotherapy correlates with survival in patients with advanced cervical cancer.
RIGHT VENTRICULAR FUNCTIONAL PARAMETERS BY CARDIAC MRI ARE ASSOCIATED WITH RIGHT VENTRICULAR FAILURE AFTER LVAD
Authors: Julia Simkowski, Ramsey Wehbe, Jack Goergen, Allen S. Anderson, Kambiz Ghafourian, Ike Stanley Okwuosa, Esther E. Vorovich, Faraz Ahmad, Anjan Tibrewala, Duc Pham, Jane Wilcox, Jonathan Rich
Journal: Journal of the American College of Cardiology (2020)
Metronomic continuous oral cyclophosphamide as second and further line in soft-tissue sarcomas (STS) of the adult.
Authors: Alessandro Comandone, Antonella Boglione, Elena Giubellino, Paola Bergnolo, Giancarlo Gino, Elena Maria Brach del Prever, Marco Turbiglio, Raimondo Piana, Paolo Pochettino, Alessandra Linari, Orietta Dal Canton, Simona Chiado Cutin, Ferdinando Garetto, Cristiano Oliva, Davide Ottaviani, Paola Pazienza
Journal: Journal of Clinical Oncology (2013)

10572 Background: In STS third line treatment is poorly defined. However many patients (pts), after aggressive therapy as first and second line progress in their disease ask to be treated. Oral cyclophosphamide (CPM) was already used in breast cancer, prostate cancer and in elderly pts with STS with favourable results. Aim of our study was to define the feasibility, tolerability and activity of oral CPM as third line and further line chemotherapy Methods: 45 pts (19 M; 26 F) with advanced or metastatic STS heavily pretreated were included. Oral CPM was given daily at total dose of 50 mg/day without interruption excepted for toxicity or progressive disease Results: Median age was 60 (32-81), histological subtypes were: leiomyosarcoma 12, liposarcoma 10, condrosarcoma 5, sinovialsarcoma 4, sarcoma NOS 4, other 10. Primary sites were: extremities 21, retroperitoneum 19, trunk 5. 41 pts were metastatic, 4 locally advanced. 41 pts were pretreated with chemotheraphy (15 were in II line, 17 in III line, 7 in IV line, 2 in V line). Median PS (ECOG) was 2 . Median duration of theraphy was 4 months (1-38). Progression free survival (PFS) ranged from 0 to 42+ months (median 4 months). Treatment was well tolerated, we registred only one episode of leucopenia G2 and one of asthenia G2. No complete responses were seen. Only 3 minimal responses and 18 stable disease were seen. Conclusions: Oral CPM showed a mild activity and good tolerability in advanced soft tissue and metastatic STS. It could be an appropriate solution as second line and further therapy and in unfit or elderly pts.
Trainees and covid-19: your questions answered
Authors: Abi Rimmer
Journal: BMJ (2020)

Will my training be disrupted?In a joint statement, UK training bodies and the General Medical Council have said that there will be increased requirements for trainees and trainers to support the management of acutely unwell patients. 1"This might result in disruption or cancellation of training activities and trainees being directed to alternative tasks and/or locations to support the covid-19 response," it said."This could mean trainees in non-acute areas being asked to
Percutaneous laser-induced thermoablation (LIT) of non-resectable lung metastases and primary lung tumors: A preliminary evaluation of technical aspects and local efficiency
Authors: M. Sponza, G. Aprile, D. Gasparini, E. Iaiza, F. De Pauli, M. Giovannoni, S. Meduri, G. Piccoli, A. Morelli, G. Fasola
Journal: Journal of Clinical Oncology (2006)

17106 Background: Surgical resection remains the standard of care for solitary lung metastasis from colorectal cancer or primitive lung tumors. Nevertheless only a small part of patients can be radically resected. Thermal ablation is a mini-invasive local treatment that can be considered an alternative approach in non-resectable lesions or inoperable patients. Methods: We present a consecutive series of thirteen patients treated with LIT from March 2004 to March 2005. Nine patients had a small (maximum diameter smaller than 5 cm) non-resectable lung carcinoma while four patients had a solitary metastasis from colorectal cancer. Median age was 70-yrs (range 55–87), male-female ratio was 2:1. After mild sedation and local anaesthesia, optical fibers were inserted directly into the tumor with CT-guided percutaneous needle placement. Each optical fiber was connected to a neodymium:yttrium-aluminium-garnet (ND:YAG) laser, which delivers concentrated light at a wave-length of 1064 nm, with a 5-Watt power and a 1800-Joule energy per single fiber. A minimum of two and a maximum of four needles were used, with a 5 to 8 mm distance from one needle to another. Results: All the patients tolerated LIT procedure well, developing a minimal pneumothorax, which did not require any treatment. Easy manageable local side-effects occurred in two cases (a mild self-limiting haemoptysis and a pleural empyema). Post-treatment CT-scan demonstrated complete thermonecrosis in all the lesions smaller than 3 cm and almost complete in the bigger ones (3 to 5 cm). All the patients are still alive, with a local tumor control rate of 100% at radiological follow-up: no local progression was observed in 10 pts with a follow-up of at least 12 months and in 3 pts with a follow-up of at least 6 months. Conclusions: Percutaneous LIT permitted a complete ablation of lung metastases and lung carcinomas with an optimal local tumor control rate at 1-year and a low complication rate. Complete necrosis was achieved only in lesions with maximum diameter smaller than 3 cm. No significant financial relationships to disclose.
BENEFIT OF GENOTYPE-GUIDED ANTI-PLATELET THERAPY IN PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION WITH STENTING: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: M Rubayat Rahman, Wasawat Vutthikraivit, Saif El Nawaa, Mohamed Elmassry, Pablo Paz, Barbara Mantilla, Pattara Rattanawong, Saranapoom Klomjit, Rasikh Ajmal, Mohammad Ansari, Scott Shurmur
Journal: Journal of the American College of Cardiology (2020)
CHARACTERISTICS OF PATIENTS DIAGNOSED WITH CARDIAC TRANSTHYRETIN AMYLOIDOSIS BY TECHNETIUM PYROPHOSPHATE UPTAKE WITHIN A HEALTHCARE SYSTEM
Authors: Angie Seo, Hyeon-Ju Ryoo Ali, Rimmy Garg, Danni Fu, Kashif Ather, Daniel Levine, Raymond R. Russell
Journal: Journal of the American College of Cardiology (2020)
Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units
Authors: Ha Uk Chung, Alina Y. Rwei, Aurélie Hourlier-Fargette, Shuai Xu, KunHyuck Lee, Emma C. Dunne, Zhaoqian Xie, Claire Liu, Andrea Carlini, Dong Hyun Kim, Dennis Ryu, Elena Kulikova, Jingyue Cao, Ian C. Odland, Kelsey B. Fields, Brad Hopkins, Anthony Banks, Christopher Ogle, Dominic Grande, Jun Bin Park, Jongwon Kim, Masahiro Irie, Hokyung Jang, JooHee Lee, Yerim Park, Jungwoo Kim, Han Heul Jo, Hyoungjo Hahm, Raudel Avila, Yeshou Xu, Myeong Namkoong, Jean Won Kwak, Emily Suen, Max A. Paulus, Robin J. Kim, Blake V. Parsons, Kelia A. Human, Seung Sik Kim, Manish Patel, William Reuther, Hyun Soo Kim, Sung Hoon Lee, John D. Leedle, Yeojeong Yun, Sarah Rigali, Taeyoung Son, Inhwa Jung, Hany Arafa, Vinaya R. Soundararajan, Ayelet Ollech, Avani Shukla, Allison Bradley, Molly Schau, Casey M. Rand, Lauren E. Marsillio, Zena L. Harris, Yonggang Huang, Aaron Hamvas, Amy S. Paller, Debra E. Weese-Mayer, Jong Yoon Lee, John A. Rogers
Journal: Nature Medicine (2020)
CARDIAC CATHETERIZATION IN PATIENTS LIVING WITH HIV
Authors: Bertrand F. Ebner, Louis Vincent, Jelani Grant, Fahim Pyarali, Alexander Toirac, Gerardo Zablah, Kunal Kapoor, Alexis Powell, Catherine Boulanger, Dushyantha Jayaweera, Michael Kolber, Barry Hurwitz, Claudia A. Martinez
Journal: Journal of the American College of Cardiology (2020)
Serial sputum induction in nontuberculous mycobacterial pulmonary disease
Authors: Michael R. Holt, Shannon H. Kasperbauer, Charles L. Daley
Journal: European Respiratory Journal (2020)

<b>Incremental detection yields of serial induced sputum samples support collection of three samples for detection of nontuberculous mycobacteria. In addition, higher colony counts on solid media are associated with markers of disease severity.</b>http://bit.ly/2Tn14Qa
GENDER BASED DISPARITIES FOR CONGESTIVE HEART FAILURE READMISSION FOLLOWING TRANS CATHETER AORTIC VALVE REPLACEMENT: A SINGLE CENTER STUDY
Authors: Anas Saad, Keerat Rai Ahuja, Mohamed M. Gad, Grant W. Reed, Rishi Puri, James Yun, Shinya Unai, Manpreet Kaur, Toshiaki Isogai, Omar Abdelfattah, Ingrid Hsiung, Johnny Chahine, Lars G. Svensson, Amar Krishnaswamy, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
EFFECTS OF SEMAGLUTIDE VERSUS COMPARATORS ON CARDIOVASCULAR EVENTS ACROSS A CONTINUUM OF BASELINE CARDIOVASCULAR RISK: COMBINED ANALYSIS OF THE SUSTAIN AND PIONEER TRIALS
Authors: Mansoor Husain, Stephen C. Bain, Anders G. Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay
Journal: Journal of the American College of Cardiology (2020)
CONTEMPORARY TREATMENT PATTERNS FOR NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS IN PATIENTS WITH AND WITHOUT CARDIOVASCULAR DISEASE
Authors: Efstratios Koutroumpakis, Randa Hamden, Anita Deswal, Poyee Tung, Vijay Nambi, Trudy Krause, David Aguilar, David Aguilar
Journal: Journal of the American College of Cardiology (2020)
LVOT OBSTRUCTION AND SEVERE AORTIC REGURGITATION CAUSED BY ANTEROLATERAL MUSCLE BUNDLE OF THE LEFT VENTRICLE: THE EMBRYOLOGIC REMNANT OF THE BULBO-ATRIOVENTRICULAR FLANGE
Authors: Ahmed Altibi, Lama Al Jebbawi, Brijesh D. Patel
Journal: Journal of the American College of Cardiology (2020)
INADEQUATELY LOW LEFT VENTRICULAR MASS IN PATIENTS WITH AORTIC VALVE STENOSIS: IMPROVED LEFT VENTRICULAR CONTRACTILITY AND CLINICAL OUTCOMES?
Authors: Nicholas Chew, Nicholas Ngiam, Benjamin Tan, Ching Hui Sia, Hui-Wen Sim, William Kong, Edgar Tay, Tiong Cheng Yeo, Kian Keong Poh
Journal: Journal of the American College of Cardiology (2020)
3D PRINTED HEART VALVES: CHALLENGES AND OPPORTUNITIES
Authors: Wilson Tzu-Yung King, Ruud Schrijver, Manoj Parimi, Theja Kudaravalli, Tej Sura, Jordan Tanner, Fayzan Ali, Brian Albers, Cirilo Sotelo-Avila, Charles Huddleston, Sridhar Condoor
Journal: Journal of the American College of Cardiology (2020)
ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION AND CARDIOGENIC SHOCK: HIGHER INCIDENCE AND MORTALITY IN WOMEN
Authors: Antonia Sambola, Manuel Anguita Sanchez, Cristina Fernández-Pérez, José Luis Bernal, Irene Buera, Francisco Marin, Albert Ariza, Francisco Javier Elola
Journal: Journal of the American College of Cardiology (2020)
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for invasive anal carcinoma in HIV-positive patients receiving highly active anti-retroviral therapy versus non-HIV patients.
Authors: Paul G. Rubinstein, Shylandra B. Sreenivasappa, Shweta Gupta, Shivi Jain, Shinoj Pattali, Jennifer Blumetti, Michael Russell Mullane
Journal: Journal of Clinical Oncology (2012)

e14590 Background: In the non-HIV population, radiotherapy (RT), fluorouracil (5FU) with mitomycin (MMC) has become the standard in the non-metastatic setting for anal carcinomas (AC). To date, most studies with AC in HIV patients (pts) are small case series where multiple chemoradiation (CRT) regimens were used and analyzed as one cohort. In addition, little data exists on the inner city HIV population. Cook County Hospital (CCH) is the largest health provider for HIV pts in Chicago and together with its outpatient clinic, the Ruth M. Rothstein CORE Center (CC) 5,500 HIV+ pts are treated per year. The County Hospital (CCH) AIDS Malignancy Project (CHAMP Study) is a retrospective study of all HIV cancer pts treated for the past 14 years. Methods: We identified all HIV+ pts with invasive AC in CHAMP cohort. We analyzed HIV characteristics, overall survival (OS), PFS and pt demographics and compared it to a HIV- cohort from the same institution. All AC treated without MMC/5FU/RT were excluded. Statistics: Time to local recurrence (TLR), time to distant metastasis (TDM), and OS data was analyzed using Kaplan-Meier analysis and a Cox Proportional Hazards model. Results: 35 HIV + and 52 HIV - pts were included. Of the HIV+ vs. HIV- pts, 89 vs. 52% were male, 82 vs. 48% were AA and the average age in HIV+ vs. HIV- was 44 vs. 52 yrs. 45 % of the HIV pts presented with stage IIIA or IIIB disease vs. 46% in HIV- pts. 15 % HIV- pts had stage IV vs. 0% HIV +. The median survival in the HIV+ vs. HIV- was 34 vs. 39 mo (p&gt;0.5). In the HIV- population, 22% survived 120 months, while no HIV pt survived over 90 months. TLR was 20 months shorter in the HIV+ arm (p&lt;0.5). OS based on CD4 count did not differ. Conclusions: HIV associated AC is an AA male disease compared to HIV- pts in the inner city. More stage IV disease was reported in the HIV- cohort, but the median survival was equal with no long-term survivors in the HIV+ arm, possibly due to TLR, which was 20 months shorter, implying more aggressive disease. Both inner city groups present late but tolerate chemotherapy equally well. Education is needed in both HIV+ and HIV- pts to diagnose the cancers early so the OS can match the national average.
PROCEDURAL AND CLINICAL OUTCOMES OF TRANSCATHETER MITRAL VALVE REPAIR USING THE MITRACLIP SYSTEM IN PATIENTS WITH SEVERE MITRAL REGURGITATION AND SMALL MITRAL VALVE AREA
Authors: Homam Ibrahim, Joseph Tovar, Illya Pushkar, Carlos Gonzalez Lengua, Jorge Fuentes, Hasan Jilaihawi, Michael Querijero, Alan Vainrib, Cezar Staniloae, Muhamed Saric, Mathew Williams
Journal: Journal of the American College of Cardiology (2020)
Influence of histological type, smoking history and chemotherapy after 1<sup>st</sup> line on treatment outcome in advanced non-small cell lung cancer
Authors: N. Yamamoto, T. Itaya, T. Takahashi, G. Asai, M. Ebisawa
Journal: Journal of Clinical Oncology (2006)

17118 Background: Primary endpoint of clinical trials of 1 st line chemotherapy in advanced non-small cell lung cancer (NSCLC) is usually used over all survival. However, we know that 2 nd line chemotherapy is prolonged survival time. Especially, Asian ethnicity, non-smokier and adenocarcinoma (Ad) were possible to be associated with survival in EGFR TKI such as gefitinib. Thus, we undertook this analysis to identify the prognostic factors of the progression free survival (PFS) and overall survival (OS) and to examine the effect of chemotherapy after 1 st line in advanced NSCLC patients. Methods: We selected the patients who were received 1 st line chemotherapy in the Shizuoka Cancer Center between October, 2002 and September 2005 and fullfilled following criteria: 1. stage IIIB or IV NSCLC, 2. no prior therapy for lung cancer, 3. chemotherapy regimen was CBDCA AUC 6 + Paclitaxel 200 mg/m 2 , 4. PS 0 or 1. Univariate and multivariate analyses were performed on possible porgnostic factors such as gender, PS, smoking history, histology (adenocarcinoma or other), and stage. Results: A total of 98 patients (35 females, median age 61 years [range 340–78], 74 adenocarcinomas, 73 smokers, 56 PS 0) fullfilled above selection criteria. 71 (78%) in these patients received 2 nd line chemothrapy (gefitinib 44%, erlotinib 4%, and docetaxel 48%). Median-PFS and MST was 4.9 months(m) and 16.1m. PFS was not significant difference in smoking history (M-PFS: smoker 5.0m, non-smoker 4.4m) and histlogical type (Ad 4.9m, others 4.7m). However, OS was significant diference in each factor(2 yr survival rate: smoker 61%, non-smoker 17%, p = .0001, Ad 39%, others 8%, P = .0001). Multivariate analysis in 71 patients received 2 nd line chemotheraoy revealed that treatment of EGFR TKI was only independent predictors of OS. Conclusions: OS of non-smoker or adenocarcinoma patients was very excellent. the usage of EGFR TKI was associate with prolongation of these OS. No significant financial relationships to disclose.